engleski

C-peptide in type 1 diabetic pregnant patients

Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the β‑cells of the pancreatic islets are selectively destroyed resulting in decline in endogenous insulin secretion. Some patients with T1DM may have some insulin secretion until their β-cells are not completely destroyed. Appropriate measure of β‑cells secretory function is concentration of C-peptide (nmol/L). Some studies proved that increased intake of some supplements (vitamins D and E, nicotinamide and n-3 polyunsaturated fatty acids, PUFA) may support preservation of β-cell function and can have protective effects on T1DM. The aim of our pilot study was to demonstrate the effect of pregnancy and n-3 PUFA on secretion of C- peptide throughout pregnancy in women with T1DM. The State Referral Centre for Diabetes in Pregnancy in the Department of OB/GYN successfully surveils and delivers diabetic pregnant women and has implemented routine tracking of C-peptide concentration. This research includes 40 pregnant women with T1DM with detectable C-peptide concentration (0, 01 nmol/L), divided in 2 groups. Study group was put on a standard diabetic diet enriched with n-3 supplement which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Control group was on standard diabetic diet without n‑3 PUFA. Preliminary results showed that during pregnancy, C-peptide concentrations were increased in both groups. But statistically significant difference was found in the study group between first and third trimester C-peptide values. To confirm these preliminary results with certainty, it is necessary to expand research with a larger number of pregnant women with T1DM.

C-peptid, diabetes type 1, n-3 polyunsaturated fatty acids, supplementation

nije evidentirano